TCHP is a four-drug chemotherapy regimen used to treat HER2-positive breast cancer. It combines two traditional chemotherapy drugs with two targeted therapies, and it’s one of the most effective options available for shrinking HER2-positive tumors before surgery. The name is simply an acronym built from the first letters of each drug in the combination.
The Four Drugs in TCHP
Each letter in “TCHP” stands for a different medication:
- T: Taxotere (docetaxel), a chemotherapy drug that interferes with cancer cells’ ability to divide
- C: Carboplatin, a chemotherapy drug that damages the DNA inside cancer cells, making it impossible for them to repair and reproduce
- H: Herceptin (trastuzumab), a targeted therapy that attaches to the HER2 protein on the surface of cancer cells and blocks the growth signals it sends
- P: Perjeta (pertuzumab), a second targeted therapy that also latches onto HER2 but at a different spot, further cutting off the signals that tell cancer cells to multiply
The two chemotherapy drugs (docetaxel and carboplatin) work broadly to slow tumor growth and kill cancer cells. The two targeted therapies (trastuzumab and pertuzumab) are more precise. They disrupt the specific chemical signals that HER2-positive cancer cells rely on to divide and spread. Using both targeted drugs together blocks the HER2 protein more completely than either one alone.
Who Receives TCHP
TCHP is prescribed for people with HER2-positive early-stage or locally advanced breast cancer. It’s most commonly used as neoadjuvant therapy, meaning it’s given before surgery to shrink the tumor and make the operation less extensive. To qualify, a tumor must test positive for overexpression of the HER2 protein, which drives roughly 20% of all breast cancers.
TCHP is not typically used for metastatic (stage IV) breast cancer, where tumors have already spread to distant organs. That situation calls for different treatment strategies. People who have had a previous breast cancer diagnosis or who have cancer in both breasts may also be treated with alternative regimens.
Treatment Schedule and Duration
A standard TCHP course runs six cycles, with each cycle lasting three weeks. On treatment day, all four drugs are given intravenously in a single session. The three-week gap between cycles gives healthy cells time to recover before the next round.
Some patients receive four cycles instead of six, depending on tumor characteristics and how well they respond. Four cycles take roughly 12 to 16 weeks to complete, while six cycles span 18 to 24 weeks. Your oncologist will determine the right number based on your specific situation, sometimes adjusting mid-course if the tumor responds quickly or side effects become difficult to manage.
After surgery, most patients continue trastuzumab (and sometimes pertuzumab) for up to a year total, even though the chemotherapy portion is finished. This extended targeted therapy helps reduce the chance of the cancer returning.
How Effective TCHP Is
The main way doctors measure TCHP’s success before surgery is something called pathologic complete response, or pCR. This means that by the time surgery happens, no cancer can be detected in the breast tissue or lymph nodes under a microscope. A higher pCR rate is strongly linked to better long-term outcomes.
In clinical trials, TCHP achieves a pCR rate of roughly 63 to 64%. That means nearly two out of three patients have no detectable cancer remaining at the time of surgery. This is significantly better than similar regimens that use only one targeted therapy instead of two. For comparison, regimens using trastuzumab alone (without pertuzumab) produce pCR rates closer to 29 to 46%, depending on the study.
Common Side Effects
Like all chemotherapy, TCHP comes with side effects. Most are manageable, but knowing what to expect helps you prepare.
Diarrhea is the most frequently reported issue, affecting about 70% of patients. The pertuzumab component is the primary driver. For most people, it stays mild to moderate. Only about 3% experience severe diarrhea that significantly disrupts daily life. Your care team will likely recommend an over-the-counter anti-diarrheal medication as a first-line treatment, along with dietary adjustments and staying well hydrated. Dose reductions of pertuzumab are not recommended, but treatment sessions can be delayed briefly if diarrhea becomes difficult to control.
Hair loss is expected with TCHP, as docetaxel is well known for causing it. Most patients lose hair on their scalp and may also notice thinning of eyebrows and eyelashes. Hair typically begins regrowing within a few months after treatment ends.
Low white blood cell counts (neutropenia) occur in about 24% of patients, with roughly 5% experiencing a severe drop. This makes you more vulnerable to infections, which is why your blood will be checked regularly during treatment. Febrile neutropenia, where a low white count is accompanied by fever and signals a potentially serious infection, occurs in about 2% of patients and requires prompt medical attention.
Fatigue, nausea, and decreased appetite are also common, though anti-nausea medications given alongside TCHP have improved substantially over the years. Most people find that fatigue builds cumulatively, meaning later cycles feel harder than earlier ones.
Heart Monitoring During Treatment
Both trastuzumab and pertuzumab can affect the heart’s pumping ability. This doesn’t happen to everyone, but it’s a known risk with HER2-targeted therapies. The concern is a decrease in the heart’s ejection fraction, which is the percentage of blood pumped out with each heartbeat.
Because of this risk, the FDA recommends heart function testing at baseline (before treatment starts) and every three months during therapy. This is done with either an echocardiogram or a MUGA scan, both of which are painless imaging tests. If your heart function drops below a certain threshold, your oncologist may pause the targeted therapy temporarily or adjust your treatment plan.
One advantage of TCHP over older breast cancer regimens is that it does not include anthracyclines, a class of chemotherapy drugs with a well-established risk of permanent heart damage. TCHP’s cardiac effects are generally reversible once treatment stops, which is a meaningful distinction for long-term heart health.
What Treatment Days Look Like
TCHP is given as an intravenous infusion at a clinic or hospital. The first session tends to be the longest because the targeted therapies require a higher initial loading dose, and staff will monitor you closely for any infusion reactions. Subsequent sessions are shorter but still typically take several hours, since four separate drugs need to be administered along with pre-medications to prevent nausea and allergic reactions.
Most people feel relatively normal on treatment day itself. Side effects like fatigue, nausea, and diarrhea tend to peak in the days following an infusion, then gradually improve before the next cycle. Many patients find that planning for a few low-energy days after each session helps them manage work, childcare, and daily responsibilities around their treatment schedule.